CN101239078A - Placenta immunoregulation medicament capsule - Google Patents
Placenta immunoregulation medicament capsule Download PDFInfo
- Publication number
- CN101239078A CN101239078A CNA2008100546458A CN200810054645A CN101239078A CN 101239078 A CN101239078 A CN 101239078A CN A2008100546458 A CNA2008100546458 A CN A2008100546458A CN 200810054645 A CN200810054645 A CN 200810054645A CN 101239078 A CN101239078 A CN 101239078A
- Authority
- CN
- China
- Prior art keywords
- placenta
- treatment
- immunoregulation medicament
- medicament capsule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a placenta immunity adjusting medicine capsule with each medical dose unit containing 1/50 to 1/10000mL placenta tissue fluid. A poultry egg serves as an attachment agent and is added with the placenta tissue fluid for full agitation. The solution is dried and then crushed into powder which is then put into capsules. The medicine capsule can stimulate the immunity action, thus achieving the aim of health care and curing and preventing diseases. As the amount of the effective ingredients is small, no adverse drug reaction is occurred. Seen through the treatment to prostatomegaly urinary retention, nephritis, epilepsy, inflammatory aches, Meniere disease, etc., the capsule achieves good result.
Description
Technical field
The present invention relates to a kind of immunoregulation medicament, be specifically related to a kind of immunoregulation medicament made from placenta interstitial fluid.Medicine of the present invention can be induced the exciting human immunoreation, to resist and to treat disease.
Background technology
Cytokine is the general designation by the protein matter of the biologically active of cell generation.By all means with cytokine as in the medicine donor, give full play to the biological action of cytokine, can be used for resisting and treating disease.With the reasonable dosage of the cytokine of trace, reasonable compatibility,, can obtain following effect by inducing the immunoreation that excites intestinal tract Pai Shi set associated lymphoid tissue:
1, antiinflammatory action
Can suppress because of the inflammation due to bacterial infection, immunity, chemistry, radiation and the physical factor.Be similar to glucocorticoid, can stop inflammatory cell (lymphocyte, granulocyte, macrophage etc.) to move to inflammation part, the reaction that stops inflammatory mediator such as kassinin kinin class, histamine, slow reacting substance etc. to take place, stablize lysosome membrane, stop complement to participate in inflammatory reaction, increase the density of blood capillary, reduce its permeability, make and ooze out minimizing, tissue injury due to the inflammation-inhibiting.
2, anti-immunologic injury
Suppress super quick immunoreation by a plurality of links, make and organize T that autoantigen replys and B cell because of clonal anerge, clone do not activate, immunity is ignored and the immunosuppressant cell effect can not be carried out immunne response, recovery is to the immunologic tolerance of autoantigen, alleviate the symptom of anaphylaxis and autoimmune disease, and reach anti-immunologic injury effect.
3, improve interior environment, improve immune defence
Immune system cans be compared to human internal environment's cleaner, and the old and feeble foreign body, metabolism foreign body and the variation foreign body that produce in the body are engulfed, handle, discharged.By immunoreactive antiinflammatory and anti-immunologic injury effect; do not suppress the performance of normal immunologic function; but strengthened activity of immune cells; make it to concentrate strength on tackling invasion source of disease thing, the ability of engulfing, remove metabolism foreign body, old and feeble foreign body and variation foreign body strengthens, the spatter property and the stability of environment in improving; make gene expression normalization; created condition for impaired tissue repair, disease is able to Lock-out, the value high to being formed with of prophylaxis of tumours.
In addition, immunoreation is to other system, and especially the central nervous system peripheral nervous system of unifying also has wide influence.
Immunoreactive antiinflammatory and anti-immunologic injury effect can replace anti-inflammatory analgesic, antihistaminic and glucocorticoid medicine under many circumstances, obtain the curative effect that medicine has.When special necessity is used glucocorticoid, unite this immunoreation and also can reduce drug dose, shorten the course of treatment.
But because the cytokine class medicine is shorter in the intravital half-life of people, the injection that need give patient's high dose repeated multiple times can obtain certain curative effect, and this way tends to cause serious toxic and side effects.
The cytokine that contains A wide selection of colours and designs such as placental globulin, multiple hormone, aminoacid and interferon, interleukin in the placenta tissue.Tradition traditional Chinese medical science custom is made powder with Placenta Hominis, is used for the treatment of weakness and becomes thin.Modern medicine then is made into injection, is used for the treatment of some chronic disease such as chronic inflammatory disease, postoperative intestinal adhesion, scar contracture and tracheitis of gynecological, department of dermatologry; Or be made into various extract injections, in order to enhancing immunity, placental peptide injection is in order to beauty treatment or the like as the gamma seroglobulinum humanum placentae injection.
But, need the injection of high dose repeated multiple times when using placenta injection, not only prevention effect is not remarkable, and drug use dosage is big, tends to occur some toxic and side effects.
Summary of the invention
The purpose of this invention is to provide a kind of placenta immunoregulation medicament capsule, this medicine can be induced challenge, demonstrates significant biological effect, is cured the disease, the purpose of diseases prevention, health care, and does not have any bad toxicity.
Based on the reasonable dosage of the cytokine of trace, by inducing the immunoreation that excites intestinal tract Pai Shi set associated lymphoid tissue, can obtain antiinflammatory action, anti-immunologic injury and improve interior environment, improve the mechanism of immune defence, the immunoregulation medicament that the placenta immunoregulation medicament capsule that the use Placenta Hominis is made and the cytokine of purification are made has the effect of different Qu Tonggong.Contain A wide selection of colours and designs in the Placenta Hominis but the cytokine of trace, (15～30KD) albumen or glycoprotein are difficult to purification and extract for low-molecular-weight.And the cytokine that contains in the placenta interstitial fluid of certain metering also can reach same significant biological effect.
Immunoregulation medicament capsule of the present invention is made by placenta interstitial fluid, contains the 1/50～1/10000mL of placenta interstitial fluid in each pharmaceutical dosage unit.
The concrete preparation method of medicament capsule of the present invention be with fowl egg for depending on agent, will placenta interstitial fluid's medicine add in the fowl egg and stir, dryly also be ground into powder, in incapsulating, contain the capsule of above-mentioned dose drug in making every.
Using method of the present invention is: each 1, every day 3～4 times, empty stomach is chewed or is swallowed.
Adopt the therapeutic modality of high dose repeated multiple times intramuscular injection placenta interstitial fluid or oral Placenta Hominis powder to compare with prior art, the effective ingredient dosage trace of placenta immunoregulation medicament capsule of the present invention, treat with oral administering mode, excite the intestinal mucosa lymphoid tissue by inducing, cause the immunoreation of whole body interlock type, can obtain antiinflammatory action, anti-immunologic injury effect and improve interior environment, improve the effect of immune defence.Be adapted to the rehabilitation of prevent disease, health of body and various acquired diseases, can be used for treating allergic disease, pain that inflammatory reaction causes, disease that chronic inflammatory disease causes, disease that nervous dysfunction causes such as mentally deranged, epilepsy etc., can also replace glucocorticoid, antihistaminic and anti-inflammatory analgesic etc. in some cases, have that acute disease is quick-acting, the therapeutic effect of chronic disease slow.
Because therefore the effective ingredient dosage trace of placenta immunoregulation medicament capsule of the present invention does not have any bad toxicity to human body.
The specific embodiment
Embodiment 1
Get the 20mL of Plancenta Histolysate's (specification: 2mL/ props up) that Handan Kang Ye pharmaceutical Co. Ltd produces, add in the 800mL egg stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, egg powder 190mg is arranged in every capsules, wherein contain the 1/50mL of placenta interstitial fluid.
Embodiment 2
Get the 1/10mL of placenta interstitial fluid and join in the 800mL egg, stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, dress egg powder 190mg wherein contains the 1/10000mL of placenta interstitial fluid in every capsules.
Embodiment 3
Get the 1mL of placenta interstitial fluid add in the 800mL egg stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, egg powder 190mg is housed in every capsules, wherein contain the 1/500mL of placenta interstitial fluid.
Embodiment 4
Get the 10mL of placenta interstitial fluid add in the 800mL egg stir, dry and be ground into egg powder, be filled in No. 2 capsules, make 1000 capsules, egg powder 190mg is housed in every capsules, wherein contain the 1/100mL of placenta interstitial fluid.
Application examples 1
The analysis and summary of placenta immunoregulation medicament capsule treatment prostate hyperplasia urine retention observation of curative effect
1, general clinical data
Since two thousand three, adopt placenta immunoregulation medicament capsule treatment prostate hyperplasia urine retention male patient 19 examples of the present invention, 55～70 years old age.Wherein 5 examples have medical history more than 5 years, acraturesis, and the urine line is thin, drench to drip incessantly, is difficult to drain, and unable, the bladder poor compliance of detrusor of bladder, bladder residual urine volume are many on inspection, once repeatedly because of the urethral catheterization of dysuria row, anti-infective therapy.6 examples are gone the bladder stoma postoperative because of prostate hyperplasia, dysuria, and slight on inspection detrusor of bladder is impaired, the bladder compliance lowers, and can drain urine.In addition 8 routine patient's medical histories are 1～3 year, and the urine line is thin, it is not smooth to urinate, and still can drain, and on inspection, detrusor of bladder does not have obviously impaired, the bladder compliance can, the bladder residual urine volume is few.
Above case all according to medical history, have a medical check-up, the anus touch shows prostate severe hypertrophy, the tough swelling of matter has by tenderness and ultrasound diagnosis etc. and makes a definite diagnosis.
2, Therapeutic Method
Adopt placenta immunoregulation medicament capsule of the present invention, 1/time, every day 3 times, oral; Bladder creating-fistula is pulled out behind unobstructed micturition.
3, criterion of therapeutical effect
Produce effects: unobstructed micturition is strong; Effectively: dysuria is obviously alleviated; Invalid: dysuria does not have improvement.
4, therapeutic effect and tracing study
The patient that 5 routine detrusor of bladder are unable, bladder poor compliance, bladder residual urine volume are many, after treatment February, urinating occurs improving, the chap of urine line, the back urine retention occurs once again because of urinary system infection, and abandons continuing treatment.
14 routine patients are after treating February in addition, and urinating occurs improving, and during to March, it is normal strong to urinate, and urinates the line chap.6 examples are pulled out bladder creating-fistula.Treat for 5～June altogether.The anus touch prostate preceding nothing of treatment obviously dwindles, but the swelling disappearance is soft flexible.Tracing study did not have recurrence in 1～5 year.
5, analysis and summary
Old-age group is two key factors of the loose morbidity of prostatic hyperplasia with the testis that function is arranged, and various factors causes the prostata tissue inflammatory reaction, causes hamartoplasia, swelling hyperemia, is the immediate cause that causes bladder outlet obstruction (BOO).
Placenta immunoregulation medicament capsule of the present invention has antiinflammatory action, through interim treatment, though the tissue of hypertrophy hypertrophy is dwindled, can make the congested alleviation of swelling, and it is soft flexible that prostate becomes, and bladder outlet obstruction (BOO) is eased, and recovers the normal voiding function.
As long as it is obviously impaired that the detrusor of bladder function does not have, the bladder compliance is good, adopts placenta immunoregulation medicament capsule treatment prostatic hyperplasia urine retention of the present invention, and existing therapeutical effect has the prevention meaning again.
Application examples 2
Placenta immunoregulation medicament capsule treatment nephritis observation of curative effect is analyzed
1, general clinical data
Since two thousand four, adopt placenta immunoregulation medicament capsule treatment nephritis 3 examples of the present invention, be the women.Wherein 1 example is 24 years old, in spring in 2004 because of suffering from Henoch Schonlein purpura nephritis, go to a doctor in the out-patient treatment of hematology of Changzhi peace hospital, therapeutic scheme: 1 oral prednisone; 2 intravenous injection calcium preparation; 3 oral Chinese medicine decocts.Patient's hormone puffiness due to deficiency build when seeing and treating patients, still there is volume anaphylactoid purpura pigmentation spots in two lower limb, chemical examination urine protein 2+, erythrocyte 2+.1 example 5 years old, because of repeated cold, chemical examination urine is unusual, hospitalizes Changzhi peace pediatric hospital treatment with nephrotic syndrome, leaves hospital after 20 days, continues out-patient treatment, therapeutic scheme: 1 oral prednisone; 2 intravenous drip Radix Salviae Miltiorrhizaes etc.; 3 oral Chinese medicine decocts.Patient's hormone puffiness due to deficiency build is lain up when seeing and treating patients, careful anti-flu, chemical examination urine protein 3+, erythrocyte 3+.1 example 32 years old, flu back facial area and extremity edema, the chemical examination urine protein-, erythrocyte 3+, the how tame hospital of going to a doctor, the positive pressure of having a blood test is normal, B ultrasonic, MRI, hepatic and renal function etc. are all no abnormal, carries out treatments such as infection, oral Chinese medicine decoct, chemically examine repeatedly urine protein-, erythrocyte 3+.Patient face portion edema is not obvious when seeing and treating patients, the slight edema of two lower limb, during walking easily tiredness, the chemical examination urine protein-, erythrocyte 3+, tentative diagnosis is a glomerulonephritis.
2, Therapeutic Method
1), adopts placenta immunoregulation medicament capsule of the present invention, 1/time, every day 3 times, (medicine) being taken before meal.
2), continue former treatment.
3, therapeutic outcome and tracing study
The Henoch Schonlein purpura nephritis patient treatment is in the time of 15 days, and two lower limb purpura pigmentation spots disappear, uncomfortable disappearance, the chemical examination urine protein-, erythrocyte-.Treat prednisone decrement after 30 days, subtracted 5mg in per 4 days, to withdrawing.Treated altogether 90 days, chemically examine repeatedly urine protein-, erythrocyte-.Tracing study did not have recurrence in 4 years.
The nephrotic syndrome patient treatment is in the time of 15 days, and spirit takes a turn for the better, and activity increases, the chemical examination urine protein-, erythrocyte-.Treat prednisone decrement after 30 days, subtracted 2.5mg in per 4 days, to withdrawing.Treated altogether 90 days, chemically examine repeatedly urine protein-, erythrocyte-.Tracing study did not have recurrence in 4 years.
The glomerulonephritis patient treatment is in the time of 20 days, and spirit takes a turn for the better, and activity increases, the chemical examination urine protein-, erythrocyte 2+.When treating 30 days, uncomfortable disappearance, edema of pair of lower extremities disappears, the slight tiredness of walking, activity increases, the chemical examination urine protein-, erythrocyte 3+; Relate it because of, the pharyngalgia of catching a cold recently, give intravenous drip penicillin treatment 10 days.During to 50 days, the patient normally works and rests, do not have uncomfortable, the chemical examination urine protein-, erythrocyte 3+.Treated altogether 80 days, chemically examine repeatedly urine protein-, erythrocyte 3+, become asymptomatic recessive hematuria patient.Now continue tracing study.
4, analysis and summary
Most glomerulonephritiies are immune-mediated property inflammation diseases.The immunoreation reaction that need cause inflammation just can cause glomerular injury and clinical symptoms thereof.
The glomerule immune complex is removed as being mesangial cell, or is engulfed by the neutrophilic granulocyte of monokaryon one macrophage, local infiltration, and pathological changes is many can be recovered.If the glomerule immune complex continues to exist or continues deposition and forms, or produces autoantibody at immunoglobulin in the immune complex in the glomerule, then can cause pathological changes to continue and development.
Placenta immunoregulation medicament capsule of the present invention is by inducing the immunoreation that excites intestinal tract Pai Shi set associated lymphoid tissue, effect with environment in antiinflammatory action, anti-immunologic injury and the improvement, strengthen activity of immune cells, made it to concentrate strength on tackling the glomerule immune complex.And can replace the glucocorticoid medicine to obtain the curative effect that medicine has under many circumstances.When special necessity is used glucocorticoid, unite this immunoreation and also can reduce drug dose, shorten the course of treatment.
Therefore, placenta immunoregulation medicament capsule treatment glomerulonephritis of the present invention has multiple meaning, gets over early treatment, and effect is good more.
Application examples 3
Placenta immunoregulation medicament capsule treatment epilepsy observation analysis
1, general clinical data
Since 2003, adopt placenta immunoregulation medicament capsule of the present invention treatment epilepsy 5 examples, after wherein 1 routine male and 1 routine women are cerebral hemorrhage, be the comprehensive grand mal of epilepsy, the intravenous injection diazepam can not controlling symptoms; 2 routine male, juvenile morbidity is looked into electroencephalogram and is found to cause the epilepsy kitchen range, takes phenytoin Sodium comparatively regularly, 1 year 1～2 time epilepsy partial seizures; 1 routine women, heating epilepsy grand mal, 2 years medical histories, outbreak in a year 3～4 times.
More than 5 routine cases all be according to medical history, epilepsy outbreak phase symptom, have a medical check-up and look into electroencephalogram or the brain CT examination is made a definite diagnosis.
2, Therapeutic Method
In epilepsy outbreak phase treatment, 1 of the thing of getting it filled is sprinkled into medicated powder in the oral cavity.
3, therapeutic effect
Adopting placenta immunoregulation medicament capsule of the present invention to treat 5 examples, all is after medicine powder is sprinkled into the oral cavity during about 15 seconds, and epilepsy stops outbreak, and it is clear realize, and the patient has significantly dizziness, health aching and tired weak.Observed 1～5 year, 32 years old male of 1 example stopping antiepileptic treatment recurrence after 2.5 years.
4, analysis and summary
Epilepsy is the of short duration brain function of a chronic repeated relapsing imbalance syndrome, with the excessive synchronous discharge of brain neuron and cause peripheral nerve unit synchronous movement to cause that repeatedly epilepsy outbreak is a feature.This altofrequency discharge is relevant with the depolarization shift that the neuron resting membrane electric potential prolongs.
Medicine of the present invention excites intestinal tract Pai Shi set lymphoid tissue to cause the immunoreation of whole body chain-type by inducing; can recover the polarization of neuron resting membrane electric potential rapidly; reparation causes epilepsy kitchen range normalization; the treatment epilepsy is fast rapid; only need about 15 seconds, and medication is convenient, medicated powder is sprinkled into the oral cavity gets final product; stable curative effect is difficult for recurrence.
Whether medicine of the present invention is not used for the treatment of the epilepsy stage of stable development as yet, have treatment and preventive effect still no matter fixed.
Application examples 4
The analysis and summary of placenta immunoregulation medicament capsule treatment inflammatory pain
1, general clinical data
Since 2002, Drug therapy acute appendicitis 27 examples of the present invention have been adopted, according to medical history, have a medical check-up and back surgical healing is made a definite diagnosis in blood routine examination etc.Treatment cholelithiasis, cholecystitis 20 examples are according to medical history, have a medical check-up and back surgical healing is made a definite diagnosis in ultrasound diagnosis etc.Headache 22 examples are sent out in the treatment spy of outbreak repeatedly, and are normal according to the headache clinical manifestation and the neurologic check of outbreak repeatedly, and inspections such as brain CT, MRI, and eliminating intracranial spaceoccupying lesion etc. is made a definite diagnosis.Treatment leg pain 19 examples that fatigue causes of having a cold are according to medical history, have a medical check-up and hematological examination is made a definite diagnosis.
2, Therapeutic Method
Acute appendicitis group and cholelithiasis, cholecystitis group are got 1 of medicine of the present invention in the pain stage of attack and are chewed and take.
Special send out the leg pain group that headache group and the fatigue of having a cold cause, 1/time, every day 3 times, (medicine) being taken before meal or chew adds 1 during the pain outbreak.
3, treatment standard
Produce effects: total pain relief, or mild pain is only arranged.Effectively: pain is obviously alleviated, and pain can be stood.Invalid: pain is not alleviated fully.
4, therapeutic effect
5, analysis and summary
Inflammatory pain and some chemical substances, mechanical irritation, antibacterial, toxin inflammation and inflammatory mediator such as histamine, kassinin kinin class, slow reacting substance, prostaglandins etc. stimulate relevant.
Placenta immunoregulation medicament capsule excites intestinal mucosa to follow Pai Shi set lymphoid tissue to cause the immunoreation of systemic immune system chain-type by inducing, can reach antiphlogistic effect, its mechanism is similar to glucocorticoid, stop inflammatory mediator such as kassinin kinin class, histamine, slow reacting substance etc. to react, tissue injury due to the inflammation-inhibiting is so there is good analgesic effect.
Application examples 5
Placenta immunoregulation medicament capsule treatment Meniere observation of curative effect is analyzed
1, general clinical data
Since 2002, placenta immunoregulation medicament capsule treatment Meniere 39 examples have been adopted, 18～60 years old age, male 21 examples, women 18 examples.Wherein the 15 routine courses of disease are 5～12 years, and once at how tame hospital therapy, often intravenous injection 654-2, lignocaine, sodium bicarbonate and take flunarizine etc. mostly can heal or take a turn for the better after treatment entirely, but recurrence is frequently, with flunarizine treat hold time longer.4 routine patients are insensitive to treating, and are dizzy heavy, and tinnitus, deafness are lighter relatively.The 24 routine courses of disease are 15 days～3 years in addition, intermittent attack, outbreak on the one is for several times, or a couple of days outbreak is once, and astasia sense in one to a few days is arranged after the outbreak.Mainly show that according to dizzy, tinnitus, deaf symptom, health check-up and electric hearing test sensorineural deafness, cranium brain CT examination no abnormality seen, X-ray sheet get rid of inspections such as cervical spondylosis and make a definite diagnosis.
2, Therapeutic Method
1/time, every day 3 times, can add 1 during paresthesia epilepsy.The course of disease is long, and the case of severe symptoms adds 1 of flunarizine, and every day 2 times is to sx.
3, criterion of therapeutical effect
Produce effects: long-term observation does not have dizzy generation, or only has slightly dizzy once in a while; Take a turn for the better: dizzy obvious alleviation, can stand, and the intermittent time is elongated; Invalid: dizzy not alleviation fully.
4, therapeutic outcome
5, analysis and summary
Adopt placenta immunoregulation medicament capsule treatment Meniere of the present invention that satisfied curative effect is arranged.Inflammatory mediator such as Meniere and histamine stimulates that acoustic nerve (cochlear nerve and vestibular nerve) causes intrinsic pressure increase in close relations, placenta immunoregulation medicament capsule can reach antiinflammatory action and improve the effect of interior environment, treat by the stage, the amelioration of inflammation reaction, the medium that diminishes inflammation stimulates, and the intrinsic pressure recovery of acoustic nerve (cochlear nerve and vestibular nerve) is normal, so curative effect is preferably arranged, and the recovery from illness back is continual and steady, is difficult for repeatedly.
Claims (2)
1, placenta immunoregulation medicament capsule is made by placenta interstitial fluid, contains the 1/50～1/10000mL of placenta interstitial fluid in each pharmaceutical dosage unit.
2, the preparation method of the described placenta immunoregulation medicament capsule of claim 1, it is characterized in that with fowl egg for depending on agent, will placenta interstitial fluid's medicine add in the fowl egg and stir the dry powder that also is ground into, in incapsulating, contain the capsule of above-mentioned dose drug in making every.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100546458A CN101239078A (en) | 2008-03-17 | 2008-03-17 | Placenta immunoregulation medicament capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100546458A CN101239078A (en) | 2008-03-17 | 2008-03-17 | Placenta immunoregulation medicament capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101239078A true CN101239078A (en) | 2008-08-13 |
Family
ID=39931090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100546458A Pending CN101239078A (en) | 2008-03-17 | 2008-03-17 | Placenta immunoregulation medicament capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101239078A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105597096A (en) * | 2016-02-02 | 2016-05-25 | 吴广印 | Application of composition of human placental tissue histosolution and allergen (antigen) solvent in preparation of injection for treating allergic diseases |
| CN106492202A (en) * | 2016-12-06 | 2017-03-15 | 葛龙海 | New active protease medicated wine |
| CN106668074A (en) * | 2017-01-11 | 2017-05-17 | 葛龙海 | Active protease medicinal liquor |
| CN109481672A (en) * | 2018-12-04 | 2019-03-19 | 青海大学 | The immune formulation and extracting method of a kind of enhancing hiding sheep aftosa vaccine immune effect |
-
2008
- 2008-03-17 CN CNA2008100546458A patent/CN101239078A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105597096A (en) * | 2016-02-02 | 2016-05-25 | 吴广印 | Application of composition of human placental tissue histosolution and allergen (antigen) solvent in preparation of injection for treating allergic diseases |
| CN106492202A (en) * | 2016-12-06 | 2017-03-15 | 葛龙海 | New active protease medicated wine |
| CN106668074A (en) * | 2017-01-11 | 2017-05-17 | 葛龙海 | Active protease medicinal liquor |
| CN109481672A (en) * | 2018-12-04 | 2019-03-19 | 青海大学 | The immune formulation and extracting method of a kind of enhancing hiding sheep aftosa vaccine immune effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krassioukov et al. | Neurogenic bowel management after spinal cord injury: a systematic review of the evidence | |
| Santos-Benito et al. | Long-term care of paraplegic laboratory mammals | |
| CN101239078A (en) | Placenta immunoregulation medicament capsule | |
| JP4272885B2 (en) | Cocaine addiction treatment | |
| US20060217405A1 (en) | Interstitial cystitis treatment | |
| CN101507736B (en) | Traditional Chinese medicine preparation for treating senile dementia, ischium lumbar, swollen glands, get-wind or the other rheumatism | |
| JP3916563B2 (en) | Treatment method including administration of substance P | |
| L. Delizonna, John P. Wincze, Brett T. Litz, Timothy A. Brown, David H. Barlow | A comparison of subjective and physiological measures of mechanically produced and erotically produced erections (or, is an erection an erection?) | |
| CN101168050B (en) | Immunity regulating medicinal composition | |
| CN1207319A (en) | Medicine for treating osteoproliferation, rheumatism and rheumatoid arthritis, and preparing method thereof | |
| RU2350341C1 (en) | Method of irritable bowel on health resort | |
| RU2268074C2 (en) | Method for treating the cases of rheumatoid arthritis | |
| Dash et al. | Matra basti the panacea: A narrative review | |
| RU2800129C1 (en) | Treatment of urogenic reactive arthritis | |
| CN104784332B (en) | A kind of preparation method of the medicament treating Chronic Urinary Tract Infection | |
| CN103550434B (en) | A kind of externally applied liniment for the treatment of rheumatism bone injury ache | |
| Care et al. | Cold Plunge: What is it? What are the benefits? | |
| Dedge et al. | Scope of Ayurveda Interventions to Improve Palliative Care Practices in Terminally Ill Cancer Patients | |
| Jadhav | A Case Study on Parikartika WSR Fissue in Ano | |
| DesRochers et al. | Rehabilitative Management of the Anterior Spinal Artery Syndrome (ASAS) Patient | |
| Harmanpreet et al. | Effect of Shampakadi Niruha Basti along with Patra Pinda Swedan in the Management of Gridharsi wsr to Sciatica | |
| Wu et al. | Some consideration on combined use of acupuncture and drug | |
| JP3927249B2 (en) | Painkiller | |
| RU1808325C (en) | Method of articular syndrome treatment in rheumatic arthritis | |
| Liu et al. | Non-drug interventions of traditional Chinese medicine in preventing type 2 diabetes: a review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080813 |